共 50 条
- [41] Direct Anti-Inflammatory and Antifibrotic Effects of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist, HM15211, in Thioacetamide-Induced Mouse Model of Liver Injury and FibrosisDIABETES, 2022, 71Kim, Jung KukLee, Jong SukKim, YohanLee, Seon MyeongKwon, HyunjooPark, EunjinChoi, JaehyukBae, SungminKim, DaejinLee, Sang HyunChoi, In Young
- [42] Anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in TAA induced mouse model of liver injury and fibrosisDIABETOLOGIA, 2022, 65 (SUPPL 1) : S400 - S401Kim, J.Lee, J.Kim, Y.Lee, S.Kwon, H.Park, E.Choi, J.Bae, S.Kim, D.Lee, S.Choi, I.
- [43] EFFECTS OF HM15211, A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, ON ANTI-INFLAMMATION AND ANTI-FIBROSIS IN TAA-INDUCED MOUSE MODEL OF LIVER INJURY AND FIBROSISHEPATOLOGY, 2022, 76 : S716 - S717Kwon, HyunjooKim, Jung KukLee, Jong SukKim, YohanPark, Eun JinChoi, JaehyukBae, Sung MinKim, Dae JinLee, Sang HyunChoi, In Young
- [44] Improvement of liver fibrosis by a novel long acting Glucagon/GLP-1/GIP triple agonist, efocipegtrutide (HM15211) in carbon tetrachloride-induced mouse model of liver injury and fibrosisJOURNAL OF HEPATOLOGY, 2023, 78 : S779 - S780Lee, Jong SukKim, YohanKim, Jung KukKwon, HyunjooPark, Eun JinKim, Jeong A.Park, Sang HyunBae, Sung MinLee, Sang HyunChoi, In Young
- [45] Direct anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in thioacetamide-induced mouse model of liver injury and fibrosisJOURNAL OF HEPATOLOGY, 2022, 77 : S469 - S469Kim, Jung KukLee, Jong SukKim, YohanLee, SeonmyeongChoi, JaehyukKwon, HyunjooPark, Eun JinBae, Sung MinKim, Dae JinLee, Sang HyunChoi, In Young
- [46] Novel Combination of a Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) and Once-Weekly Basal Insulin (HM12460a) Offers Improved Glucose Lowering and Weight Loss in a Diabetic Animal ModelDIABETES, 2018, 67Kim, Jung KukLee, Jong SukChoi, JaehyukJung, Sung YoubLee, Sang HyunChoi, In YoungKim, Sun Jin
- [47] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Ultra-Long-Acting GLP-1 Receptor Agonist (ZT002) in Healthy SubjectsDIABETES, 2024, 73Zhang, YuanyuanXu, XiusenMcLendon, KristiWong, Alex H. L.Zhang, YuyingZhang, Xujia
- [48] Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of an Optimized Dual GLP-1/GIP Receptor Agonist (BGM0504) in Healthy Subjects-A Phase Ia, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose StudyDIABETES, 2024, 73Yuan, JiandongHuang, YangqingDing, HaifengJiang, Xiaohui
- [49] Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects-A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) StudyDIABETES, 2023, 72He, KunWei, FangChen, HongZhang, YanyanSheng, ZhenWen, Qing
- [50] Safety, Tolerability, Pharmacokinetics, and Insulinotropic Activity of Single Subcutaneous Doses of LY2189265, a Long-Acting Glucagon-Like Peptide 1 (GLP-1) Analog in Healthy SubjectsDIABETES, 2009, 58 : A157 - A157Barrington, PhilipChien, Jenny Y.Tibaldi, FabianShowalter, H. D. HollilnsSchneck, Karen B.Ellis, Bernice